Current Report Filing (8-k)
December 05 2022 - 08:01AM
Edgar (US Regulatory)
0001498382 false 0001498382 2022-12-05
2022-12-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
December 5, 2022
KINTARA THERAPEUTICS, INC.
(Exact
name of Registrant as Specified in Its Charter)
|
Nevada |
|
001-37823 |
|
99-0360497 |
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number) |
|
(IRS
Employer
Identification
No.)
|
| |
|
|
|
|
|
|
|
9920 Pacific Heights Blvd,
Suite 150
San Diego,
CA
92121
|
|
|
|
|
|
(Address
of principal executive offices) |
|
|
Registrant’s
Telephone Number, Including Area Code:
(858)
350-4364
(Former
name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
| |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4©)
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered |
|
Common Stock |
|
KTRA |
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§ 240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
|
Item
2.02 |
Results
of Operations and Financial Condition. |
As
previously disclosed, Kintara Therapeutics, Inc. (the “Company”)
paused its REM-001 program in Cutaneous Metastatic Breast Cancer to
conserve cash which will be used to support the funding of the
Company’s ongoing international registrational study for VAL-083 in
glioblastoma. The Company anticipates announcing topline data
around the end of calendar year 2023. By pausing the REM-001
program, the Company expects to save approximately $3.0 million
through calendar year 2023. Additionally, the Company recently
reviewed and reduced expenses in other areas. As a result, and
based on current operating plans, the Company expects that its cash
and cash equivalents as of September 30, 2022 are sufficient to
finance its anticipated cash requirements into the third quarter of
calendar year 2023 and reduced cash required to enter calendar year
2024 to approximately $3.0 million.
|
Item
7.01 |
Regulation
FD Disclosure. |
See
“Item 2.02 Results of Operations and Financial Condition”
above.
The
information in this Current Report on Form 8-K under Items 2.02 and
7.01 is being furnished to the Securities and Exchange Commission,
and shall not be deemed to be “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section, and shall not be deemed
to be incorporated by reference into any filing under the
Securities Act of 1933, as amended, or the Securities Exchange Act
of 1934, as amended, except as shall be expressly set forth by a
specific reference in such filing.
The Company has prepared presentation materials (the “Investor
Presentation”) in connection with management presentations to
describe its business. A copy of the Investor Presentation has been
posted to the Company’s website and is attached as Exhibit 99.1
hereto.
|
Item
9.01 |
Financial
Statements and Exhibits. |
(d)
Exhibits
|
Exhibit
No. |
|
Description |
|
|
|
|
|
99.1
|
|
Investor Presentation
|
|
104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL
document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
KINTARA
THERAPEUTICS, INC. |
| |
|
|
|
Date:
December 5, 2022 |
By: |
/s/
Scott Praill |
|
|
Name: |
Scott Praill |
|
|
Title: |
Chief Financial Officer |
Kintara Therapeutics (NASDAQ:KTRA)
Historical Stock Chart
From Feb 2023 to Mar 2023
Kintara Therapeutics (NASDAQ:KTRA)
Historical Stock Chart
From Mar 2022 to Mar 2023
